MAPT and Alzheimer disease: This study demonstrates the independent and combined value of neuroimaging biomarkers for tau pathology (18F-AV-1451 PET), neuroinflammation (11C-PK11195 PET) and brain atrophy (structural MRI), in predicting longitudinal cognitive decline in patients with Alzheimer’s disease.